Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations | MicrobiomeTrials← Back to trialsNCT07566195
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-05-05Est. Completion: 2028-12-29
Enrollment target: 82 participants Locations- Research Site, Aix-en-Provence, France
- Research Site, Brest, France
- Research Site, Colmar, France
- Research Site, Gleizé, France
- Research Site, Grenoble, France
- Research Site, Lyon, France
- Research Site, Marseille, France
- Research Site, Montpellier, France
- Research Site, Pessac, France
- Research Site, Pringy, France
- Research Site, Quimper, France
- Research Site, Saint-Herblain, France
- Research Site, Toulouse, France
Other microbiome trials you might be interested in
SARS-CoV-2Influenza, HumanRespiratory Syncytial Virus InfectionsRespiratory Distress SyndromeSystemic Inflammatory Response Syndrome
The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B)…
Alcalá de Henares, SpainEst. completion Oct 2, 2026
Pulmonary Disease (COPD), Chronic ObstructiveLung Resection Surgery
This study investigates the effects of three extrinsic PEEP settings-5 cmH2O, 0 cmH2O, and an individualized PEEP (70% o…
Multiple LocationsEst. completion May 31, 2027